去勢療法抗性攝護腺癌近期治療指引與藥物介紹

張嘉哲 ； 鍾立民

《臨床醫學月刊》 84卷3期 (2019/09) Pp. 613-622

https://doi.org/10.6666/ClinMed.201909_84(3).0101

摘要

攝護腺癌是男性中最常見的惡性腫瘤，也是癌症死亡的主要原因。由於近年的檢查及藥物的進步，使得對攝護腺癌有更佳的了解，而在治療去勢療法抗性攝護腺癌的藥物不斷的進步，此篇綜論主要介紹目前對去勢療法抗性的攝護腺癌近期治療指引與藥物。

關鍵字

攝護腺癌（prostate cancer） ； 攝護腺癌藥物（prostate cancer drug treatment） ； 轉移性去勢療法抗性攝護腺癌（metastatic castration resistant prostate cancer, mCRPC）

參考文獻

2 Marugame T, Katanoda K. International comparisons of cumulative risk of breast and prostate can cer, from cancer incidence in fi ve continents Vol VIII. Jpn J Clin On-col 2006;36:399-400.

3.Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castra tion-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, dou ble-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13: 983-92.

4.Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with meta static castrationresistant prostate cancer: exploratory analysis of data from the COU-AA-301 ran domised trial. Lancet Oncol 2012;13:1210-17.

5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.

6. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus pla-cebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, dou-ble-blind, placebocontrolled phase 3 study. Lancet Oncol 2015;16:152-60.